Abstract:This extensive AWMF 085-002 S2e-guideline "First Trimester Diagnosis and Therapy @ 11 – 13 +6 Weeks of Gestation" has systematically analyzed high-quality studies and publications and the existing evidence (evidence tables) and produced recommendations (level of recommendation, level of evidence, strength of consensus). This guideline deals with the following topics in the context of the 11 – 13 +6 weeks scan: the legal basis, screening for anatomical malformations, screening for chromosomal defects, quality assessment and audit, screening for preeclampsia and FGR, screening for preterm birth, screening for abnormally invasive placenta (AIP) and placenta accreta spectrum (PAS), screening for velamentous cord insertion and vasa praevia, screening for diabetes mellitus and LGA. Screening for complications of pregnancy can best be carried out @ 11 – 13 +6 weeks of gestation. The issues of how to identify malformations, chromosomal abnormalities and certain disorders of placentation (high blood pressure and proteinuria, intrauterine growth retardation) have been solved. The problem of how to identify placenta percreta and vasa previa has been partially solved. What is still unsolved is how to identify disorders of glucose metabolism and preterm birth. In the first trimester, solutions to some of these problems are available: parents can be given extensive counselling and the risk that a pregnancy complication will manifest at a later stage can be delayed and reduced. This means that screening is critically important as it helps in decision-making about the best way to manage pregnancy complications (prevention and intervals between follow-up examinations). If no treatment is available and if a termination of pregnancy is considered, the intervention can be carried out with far lower complications compared to the second trimester of pregnancy. In most cases, further examinations are not required and the parents can be reassured. A repeat examination at around week 20 of gestation to complete the screening for malformations is recommended. Note: The guideline will be published simultaneously in the official journals of both professional societies (i.e. Ultraschall in der Medizin/European Journal of Ultrasound for the DEGUM and Geburtshilfe und Frauenheilkunde for the DGGG). Received: 17 February 2024 Accepted: 04 March 2024 Article published online: 01 October 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

EP17.23: The connection between first trimester biochemical screening results and the risk of neonatal complications post‐delivery

First-Trimester Screening's Role in Identifying Neonatal Complications

EP17.65: Evaluating first trimester PAPP‐A and free b‐HCG as risk factors for preterm membrane rupture

EP17.16: Screening for low‐tract genital infections in asymptomatic women at increased risk for preterm birth

EP17.37: Low fetal fraction of cfDNA and obstetric complications in screening centre Gennet 2019–2022

EP18.29: First trimester screening at conditions of limited resources

EP18.38: Double serological test values in first trimester screening in spontaneous pregnancies versus assisted reproduction techniques

EP18.07: Repeat cell‐free DNA testing in the third trimester after discordant high‐risk results

EP17.33: Clinical utility of first trimester combined screening for gestational diabetes using a point of care system

OP16.03: First trimester ultrasound markers for the prediction of adverse pregnancy outcomes in monochorionic diamniotic pregnancies

EP01.12: AI demonstrates high detection in first trimester screening for spina bifida

EP18.05: First trimester referral ultrasound following the introduction of the guidelines of the SIEOG: focus on false positives and false negatives

EP17.54: Assessment of the angiogenic ratio versus glycosylated fibronectin in predicting adverse neonatal outcome in women with suspected pre‐eclampsia

Firsttrimester Diagnosis and Therapy @ 11 – 13+6 Weeks of Gestation – Part 1Ersttrimester Diagnostik und Therapie @ 11 – 13+6 Schwangerschaftswochen – Teil 1

OC16.02: *Improving the early detection of spina bifida using first trimester sonographic markers: diagnostic accuracy based on 480,000 examinations

EP18.04: Postpartum placental cytogenetic analyses from pregnancies with discordant cell‐free DNA screening results

Firsttrimester Diagnosis and Therapy @ 11–13+6 Weeks of Gestation – Part 1Ersttrimester Diagnostik und Therapie @ 11–13+6 Schwangerschaftswochen – Teil 1

Firsttrimester Diagnosis and Therapy @ 11 – 13+6 Weeks of Gestation – Part 2Ersttrimester Diagnostik und Therapie @ 11 – 13+6 Schwangerschaftswochen – Teil 2

First-Trimester Ultrasound Screening in Routine Obstetric Practice

First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects

EP07.28: Routine screening for fetal limb abnormalities in the first trimester